Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis

Neurodegenerative Diseases

Volumn 5, Issue 1, 2007, Pages 38-52

  'T Hart, Bert A ^a,b   Hintzen, Rogier Q ^b   Laman, Jon D ^b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presenting cell; C type lectin receptor; Cervical lymph node; Dendritic cell; Immune mediated inflammatory disease; Toll like receptor

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CNTO 1275; CYTOKINE; INTERLEUKIN 12P40; INTERLEUKIN 12P40 MONOCLONAL ANTIBODY; INTERLEUKIN 23P40; INTERLEUKIN 23P40 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5D12; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; CALLITHRIX JACCHUS; DISEASE COURSE; DRUG ACTIVITY; DRUG SCREENING; EXPERIMENTAL STUDY; IMMUNOTHERAPY; IN VIVO STUDY; LOADING DRUG DOSE; MARMOSET; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; MULTIPLE SCLEROSIS; PRIMATES; TREATMENT OUTCOME;

EID: 37149036853     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000109937     Document Type: Review

References (72)

1. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
2. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
3. Lutz MB, Schuler G: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-449.
4. Geijtenbeek TB, van Vliet SJ, Engering A, 't Hart BA, van Kooyk Y: Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004;22:33-54.
5. 't Hart BA, van Kooyk Y: Yin-Yang regulation of autoimmunity by DCs. Trends Immunol 2004;25:353-359.
6. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC: Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-779.
7. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002;196:1627-1638.
8. Mahnke K, Qian Y, Knop J, Enk AH: Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003;101:4862-4869.
9. Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H: An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 2003;171:4920-4926.
10. 't Hart BA, van Meurs M, Brok HP, Massacesi L, Bauer J, Boon L, Bontrop RE, Laman JD: A new primate model for multiple sclerosis in the common marmoset. Immunol Today 2000;21:290-297.
11. 't Hart BA, Laman JD, Bauer J, Blezer ED, van Kooyk Y, Hintzen RQ: Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol 2004;3:589-597.
12. 't Hart BA, Smith P, Amor S, Strijkers GJ, Blezer ELA: MRI-guided immunotherapy development for multiple sclerosis in a primate. Drug Discov Today 2005;11:58-66.
13. Sachs DH: Tolerance: of mice and men. J Clin Invest 2003;111:1819-1821.
14. 't Hart B, Amor S, Jonker M: Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discov Today 2004;9:517-524.
15. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93:2499-2504.
16. Howard LM, Miga AJ, Vanderlugt CL, Dal Canto MC, Laman JD, Noelle RJ, Miller SD: Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999;103:281-290.
17. Gran B, Zhang GX, Rostami A: Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol 2004;24:111-128.
18. 't Hart BA, Amor S, Bajramovic JJ: Modeling CNS inflammatory diseases in primates. Screening trends. Drug Discov 2005;206:36-38.
19. Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-2738.
20. Compston A, Coles A: Multiple sclerosis. Lancet 2002;359:1221-1231.
21. Lassmann H, Ransohoff RM: The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004;25:132-137.
22. Brok HP, Bauer J, Jonker M, Blezer E, Amor S, Bontrop RE, Laman JD, 't Hart BA: Nonhuman primate models of multiple sclerosis. Immunol Rev 2001;183:173-185.
23. Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D, Cheung SW, Mobley WC, Fisher S, Genain CP: Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000;191:1799-1806.
24. 't Hart BA, Vogels JT, Bauer J, Brok HPM, Blezer E: Non-invasive measurement of brain damage in a primate model of multiple sclerosis. Trends Mol Med 2004;10:85-91.
25. Blezer EL, Bauer J, Brok HP, Nicolay K, 't Hart BA: Quantitative MRI-pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis. NMR Biomed 2007;20:90-103.
26. 't Hart BA, Bauer J, Muller HJ, Melchers B, Nicolay K, Brok H, Bontrop RE, Lassmann H, Massacesi L: Histopathological characterization of magnetic resonance imaging - detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am J Pathol 1998;153:649-663.
27. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H: Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-796.
28. Mancardi G, 't Hart B, Roccatagliata L, Brok H, Giunti D, Bontrop R, Massacesi L, Capello E, Uccelli A: Demyelination and axonal damage in a non-human primate model of multiple sclerosis. J Neurol Sci 2001;184:41-49.
29. Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM: Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005;128:2713-2721.
30. Peterson JW, Bo L, Mork S, Chang A, Trapp BD: Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
31. Delarasse C, Daubas P, Mars LT, Vizler C, Litzenburger T, Iglesias A, Bauer J, Della Gaspera B, Schubart A, Decker L, Dimitri D, Roussel G, Dierich A, Amor S, Dautigny A, Liblau R, Pham-Dinh D: Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest 2003;112:544-553.
32. Antunes SG, de Groot NG, Brok H, Doxiadis G, Menezes AA, Otting N, Bontrop RE: The common marmoset: a new world primate species with limited Mhc class II variability. Proc Natl Acad Sci USA 1998;95:11745-11750.
33. Doxiadis GG, van der Wiel MK, Brok HP, de Groot NG, Otting N, 't Hart BA, van Rood JJ, Bontrop RE: Reactivation by exon shuffling of a conserved HLA-DR3-like pseudogene segment in a new world primate species. Proc Natl Acad Sci USA 2006;103:5864-5868.
34. 24-36 is presented by a monomorphic MHC class II molecule. J Immunol 2000;165:1093-1101.
35. Villoslada P, Abel K, Heald N, Goertsches R, Hauser SL, Genain CP: Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. Eur J Immunol 2001;31:2942-2950.
36. de Vos AF, van Meurs M, Brok HP, Boven LA, Hintzen RQ, van der Valk P, Ravid R, Rensing S, Boon L, 't Hart BA, Laman JD: Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol 2002;169:5415-5423.
37. Fabriek BO, Zwemmer JN, Teunissen CE, Dijkstra CD, Polman CH, Laman JD, Castelijns JA: In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 2005;161:190-194.
38. 't Hart BA, Brok HP, Amor S, Bontrop RE: The major histocompatibility complex influences the ethiopathogenesis of MS-like disease in primates at multiple levels. Hum Immunol 2001;62:1371-1381.
39. Laman JD, van Meurs M, Schellekens MM, de Boer M, Melchers B, Massacesi L, Lassmann H, Claassen E, 't Hart BA: Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J Neuroimmunol 1998;86:30-45.
40. Aloisi F, Serafini B, Adorini L: Glia-T cell dialogue. J Neuroimmunol 2000;107:111-117.
41. Aloisi F, Ria F, Adorini L: Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000;21:141-147.
42. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F: Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000;157:1991-2002.
43. Feldmann M, Steinman L: Design of effective immunotherapy for human autoimmunity. Nature 2005;435:612-619.
44. Feldmann M, Maini RN: Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-196.
45. Stokkers PC, Hommes DW: New cytokine therapeutics for inflammatory bowel disease. Cytokine 2004;28:167-173.
46. McKenzie BS, Kastelein RA, Cua DJ: Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23.
47. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-β induces development of the T(H)17 lineage. Nature 2006;441:231-234.
48. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R: Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005;237:123-130.
49. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W, Churakovsa T, Low J, Presta L, Hunter CA, Kastelein RA, Cua DJ: Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006;116:1317-1326.
50. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
51. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922.
52. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ: The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994;15:406-411.
53. Laman JD, Claassen E, Noelle RJ: Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 1996;16:59-108.
54. van Kooten C, Banchereau J: Functional role of CD40 and its ligand. Int Arch Allergy Immunol 1997;113:393-399.
55. Becher B, Durell BG, Miga AV, Hickey WF, Noelle RJ: The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med 2001;193:967-974.
56. Chang JT, Segal BM, Shevach EM: Role of costimulation in the induction of the IL-12/IL-12 receptor pathway and the development of autoimmunity. J Immunol 2000;164:100-106.
57. Constantinescu CS, Hilliard B, Wysocka M, Ventura ES, Bhopale MK, Trinchieri G, Rostami AM: IL-12 reverses the suppressive effect of the CD40 ligand blockade on experimental autoimmune encephalomyelitis (EAE). J Neurol Sci 1999;171:60-64.
58. Brok HP, Van Meurs M, Blezer E, Schantz A, Peritt D, Treacy G, Laman JD, Bauer J, 't Hart B: Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002;169:6554-6563.
59. 't Hart BA, Brok HP, Remarque E, Benson J, Treacy G, Amor S, Hintzen RQ, Laman JD, Bauer J, Blezer EL: Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J Immunol 2005;175:4761-4768.
60. Kwekkeboom J, De Boer M, Tager JM, De Groot C: CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells. Immunology 1993;79:439-444.
61. Laman JD, 't Hart BA, Brok H, Meurs M, Schellekens MM, Kasran A, Boon L, Bauer J, Boer M, Ceuppens J: Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur J Immunol 2002;32:2218-2228.
62. Boon L, Laman JD, Ortiz-Buijsse A, den Hartog MT, Hoffenberg S, Liu P, Shiau F, de Boer M: Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 2002;174:53-65.
63. Boon L, Brok HP, Bauer J, Ortiz-Buijsse A, Schellekens MM, Ramdien-Murli S, Blezer E, van Meurs M, Ceuppens J, de Boer M, 't Hart BA, Laman JD: Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 2001;167:2942-2949.
64. Haanstra KG, Ringers J, Sick EA, Ramdien-Murli S, Kuhn EM, Boon L, Jonker M: Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003;75:637-643.
65. Haanstra KG, Sick EA, Ringers J, Wubben JA, Kuhn EM, Boon L, Jonker M: Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005;79:1623-1626.
66. Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, Boer M, Geboes K, Rutgeerts P, Ceuppens JL: Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005;22:111-122.
67. Couzin J: Drug discovery. Magnificent obsession. Science 2005;307:1712-1715.
68. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE, Mascelli MA: A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-1044.
69. Massacesi L, Genain CP, Lee-Parritz D, Letvin NL, Canfield D, Hauser SL: Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. Ann Neurol 1995;37:519-530.
70. Fluegel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, Ellwart JW, Willem M, Lassmann H, Wekerle H: Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001;14:547-560.
71. Greter M, Heppner FL, Lemos MP, Odermatt B, Goebels N, Laufer T, Noelle RJ, Becher B: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005;11:328-334.
72. Harling-Berg CJ, Park TJ, Knopf PM: Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol 1999;101:111-127.